University of Miami

Johns Hopkins University

University Of Modena And Reggio Emilla—unimore

Paolo Serafini

Pirouz Daftarian

Angel Kaifer

Vincenzo Bronte

Jennifer Vella

Serena Zilio

Pirouz Mohammad Daftarian

Wei Ping Li

Ivan M Borrello

Kimberly A Noonan

Norma Sue Kenyon

Victor L Perez

Vance Paul Lemmon

Alessia Zoso

Midhat Abdulreda

Andrea Grilli

Cristian Taccioli

Jimmy Caroli

Silvio Bicciato

Adriana De La Fuente

Dimitri Van Simaeys

Bonnie Beth Blomberg

Wei Li

Raquibul Chowdhury

Ivan Marquest Borrello

Kimberly Ann Noonan

The present disclosure provides materials and methods for the delivery of therapeutic nucleic cells (and imaging agents) to tissues.

Materials and methods for the delivery of therapeutic nucleic acids to tissues

Described herein are nanoparticle-based compositions, kits and methods and platforms for delivering one or more nucleic acids to a cell.

Nanoparticle conjugates and uses thereof

Described herein are nanoparticle-based compositions, kits and methods and platforms for delivering one or more nucleic acids to a myeloid cell.

Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells). Antigens may be, for example, DNA that results in expression of the gene of interest and induction of a robust and specific immune response to the expressed protein in a subject (e.g., mammal). Antigens may also be immunogenic peptides or polypeptides that are processed and presented. In one embodiment, a nanoparticle-based method to deliver antigens in vivo as described herein includes injection of a vaccine composed of a DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide conjugated to a charged dendrimer (e.g., PADRE-derivatized dendrimer) that is also conjugated to a T helper epitope (e.g., PADRE). Negatively-charged plasmids bind naturally to a positively-charged PADRE-dendrimer, while peptide or polypeptide antigens can be chemically linked to the PADRE-dendrimer if they are not negatively-charged. Alternatively, negatively-charged dendrimers may be used. The compositions, kits, vaccines and methods described herein have both prophylactic and treatment applications, i.e., can be used as a prophylactic to prevent onset of a disease or condition in a subject, as well as to treat a subject having a disease or condition. A vaccine as described herein can be used to mount an immune response against any infectious pathogen or cancer.

Vaccine compositions and methods of use thereof

The invention features methods and compositions featuring a PDE5 inhibitor for treating or preventing immunological-mediated disease in a subject.

PDE5 inhibitor compositions and methods for immunotherapy

Growing community of inventors

Miami Shores, FL, United States of America

Paolo Serafini